Yeji
NDA/BLA filedconf 0.95

adx-2191 — NDA/BLA filed

$ALDX · Aldeyra Therapeutics, Inc. · primary vitreoretinal lymphoma
Event date
Date TBD
Sponsor runway
38 mo
$65.0M liquid

Evidence

“FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma”
Source: Press release · 2023-03-02View press release ↗

Comparable historical nda/bla fileds· last 5 years · same indication

TickerDrugDateOutcome
$ALDXadx-21912023-03-02unknown

Recent insider activity· ±90 days

No insider Form 4 activity reported on $ALDX in the 90 days around this event.
← All catalysts for $ALDX